TNYATenaya Therapeutics, Inc.

Nasdaq tenayatherapeutics.com


$ 4.72 $ 0.00 (0 %)    

Thursday, 02-May-2024 12:09:24 EDT
QQQ $ 423.96 $ -1.40 (-0.33 %)
DIA $ 380.15 $ -1.37 (-0.36 %)
SPY $ 502.21 $ -2.19 (-0.43 %)
TLT $ 88.70 $ 0.48 (0.54 %)
GLD $ 212.87 $ 0.41 (0.19 %)
$ 4.68
$ 4.72
$ 0.00 x 0
$ 0.00 x 0
$ 4.67 - $ 4.77
$ 1.66 - $ 8.09
155,345
na
345.32M
$ 2.39
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-18-2024 12-31-2023 10-K
2 11-08-2023 09-30-2023 10-Q
3 08-09-2023 06-30-2023 10-Q
4 05-10-2023 03-31-2023 10-Q
5 03-08-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-10-2022 06-30-2022 10-Q
8 05-11-2022 03-31-2022 10-Q
9 03-23-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 09-08-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 chardan-capital-reiterates-buy-on-tenaya-therapeutics-maintains-20-price-target

Chardan Capital analyst Geulah Livshits reiterates Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $20 price target.

 canaccord-genuity-maintains-buy-on-tenaya-therapeutics-lowers-price-target-to-18

Canaccord Genuity analyst Whitney Ijem maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and lowers the price target fr...

 hc-wainwright--co-reiterates-buy-on-tenaya-therapeutics-maintains-18-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $18 p...

 tenaya-therapeutics-q4-eps-040-beats-044-estimate

Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $...

 tenaya-therapeutics-publishes-tn-401-gene-therapy-preclinical-data-in-nature-communications-medicine

TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricula...

 blend-labs-reports-q4-results-joins-alta-equipment-despegarcom-and-other-big-stocks-moving-higher-on-friday

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Friday. Shares of Blend Labs, Inc. (NASDAQ: BLN...

 tenaya-therapeutics-publishes-preclinical-hdac6-inhibitor-data-for-heart-failure-with-preserved-ejection-fraction-in-nature-communications

Highly selective Small Molecule HDAC6 Inhibitor Effectively Reversed Heart Failure and Improved Diastolic Heart Function Alone ...

 why-fluor-shares-are-trading-lower-by-around-8-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results.

 tenaya-therapeutics-announces-pricing-of-50m-underwritten-offering-of-8888890-shares-of-its-common-stock-at-an-offering-price-of-450-per-share

Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...

 why-commscope-shares-are-trading-lower-by-around-7-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal L...

 leerink-partners-initiates-coverage-on-tenaya-therapeutics-with-outperform-rating-announces-price-target-of-7

Leerink Partners analyst Mani Foroohar initiates coverage on Tenaya Therapeutics (NASDAQ:TNYA) with a Outperform rating and ...

 tenaya-therapeutics-q3-eps-039-beats-047-estimate

Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $...

 tenaya-therapeutics-announces-fda-clearance-to-begin-clinical-testing-of-tn-401-gene-therapy-for-the-treatment-of-pkp2-associated-arrhythmogenic-right-ventricular-cardiomyopathy

PKP2 Mutations Are the Leading Cause of ARVC, a Dangerous Condition Linked to Sudden Cardiac Arrest in Young People Estimated t...

 tenaya-therapeutics-presents-new-clinical-and-preclinical-data-from-hdac6-inhibitor-program-tn-301-for-the-potential-treatment-of-heart-failure-with-preserved-ejection-fraction-at-the-2023-hfsa-annual-scientific-meeting

TN-301 Demonstrates Tolerability, Potential for Once Daily Dosing, Target Engagement and Selectivity for HDAC6 in Phase 1 Clini...

 hc-wainwright--co-reiterates-buy-on-tenaya-therapeutics-maintains-18-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $18 p...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION